Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the recipient of unusually large options trading on Thursday. Traders ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

A new study shows how an anticancer drug triggers an “outside in” signal that gets it sucked into a cancer cell.

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...